Parkinson ‘s disease
MeiraGTx and Hologen AI Form $430M Collaboration to Advance Parkinson’s Gene Therapy
gene therapy, Parkinson’s disease, artificial intelligence, clinical trials, biotechnology partnership
FDA Approves Onapgo: Breakthrough Infusion Device for Advanced Parkinson’s Disease
Onapgo, apomorphine hydrochloride, Parkinson’s disease, subcutaneous infusion, motor fluctuations, FDA approval, Supernus Pharmaceuticals
Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension
Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro
Medtronic Launches Adaptive Brain Stimulation for Parkinson’s Disease Following EU Approval
Medtronic, BrainSense, Adaptive Deep Brain Stimulation, Parkinson’s Disease, EU Approval, CE Mark
Roche’s Prasinezumab Fails Primary Endpoint in Phase 2b Parkinson’s Trial, Shows Promising Trends
Roche, Prothena, Parkinson’s disease, prasinezumab, alpha-synuclein, phase 2b trial, PADOVA study
Roche’s Parkinson’s Drug Fails Second Mid-Stage Trial, Yet Shows Promising Trends
Roche, Parkinson’s disease, prasinezumab, clinical trial failure, promising trends, further exploration
UCB and Novartis Discontinue Development of Parkinson’s Disease Drug After Phase 2 Failure
UCB, Novartis, Parkinson’s disease, drug development, Phase 2 failure, UCB0599, UCB7853
GSK Enters Strategic Alliance with Vesalius Therapeutics for Parkinson’s Disease Treatments
GSK, Vesalius Therapeutics, Parkinson’s disease, neurodegenerative diseases, strategic alliance, small molecule program
MeiraGTx’s Gene Therapy Shows Significant Improvements in Motor Function and Quality of Life in Parkinson’s Disease Trial
MeiraGTx, Gene Therapy, Parkinson’s Disease, AAV-GAD, Motor Function, Quality of Life, Clinical Trial, Phase 2 Trial, Neurodegenerative Disease, Dopamine Replacement, GABA Production
Vanqua Bio Advances Experimental Parkinson’s Therapy with VQ-101, Bolsters Leadership Team
Vanqua Bio, VQ-101, Parkinson’s disease, GBA gene mutations, GCase activator, Neurodegenerative diseases, Clinical trials, Lysosomal dysfunction, Alpha-synuclein accumulation